Evidence map›Paper›PMID 41419829›Full record

ArticleBMC infectious diseases2025

Interferon therapy-induced reduction in PD-1 + CD8 + and CD160 + CD8 + T cells is associated with functional cure in hepatitis B.

Daqiong Zhou, Jiangyu Liu, Jianru Jia, Hong Li, Ling Qin, Zichen Zhang, Zhenhuan Cao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Daqiong Zhou *Beijing Youan Hospital, Capital Medical University, No.8, Xitou Alley, Outer, You'an Gate, Fengtai, Beijing, China.
Jiangyu Liu *Beijing Youan Hospital, Capital Medical University, No.8, Xitou Alley, Outer, You'an Gate, Fengtai, Beijing, China.
Jianru JiaBaoding People's Hospital, Baoding, Hebei Province, China.
Hong LiBeijing Youan Hospital, Capital Medical University, No.8, Xitou Alley, Outer, You'an Gate, Fengtai, Beijing, China.
Ling QinBeijing Youan Hospital, Capital Medical University, No.8, Xitou Alley, Outer, You'an Gate, Fengtai, Beijing, China.
Zichen ZhangBeijing Youan Hospital, Capital Medical University, No.8, Xitou Alley, Outer, You'an Gate, Fengtai, Beijing, China.
Zhenhuan CaoBeijing Youan Hospital, Capital Medical University, No.8, Xitou Alley, Outer, You'an Gate, Fengtai, Beijing, China. caozhenhuanyu@mail.ccmu.edu.cn.

Funding

Beijing high-level Public Health Technical Talent Construction Project 03-23Capital's Funds for Health Improvement and Research 2024-1-2182Laboratory for Clinical Medicine, Capital Medical University SYLH2023-04
6 · The paper itself

Abstract

BACKGROUND AND

aimsHBsAg seroclearance is a key indicator of functional cure in chronic HBV. We evaluated the efficacy of pegylated interferon-α (Peg-IFN-α) in HBeAg-negative patients and its association with T-cell subsets.

methodsWe retrospectively analyzed 618 patients, 34 of whom underwent longitudinal immune profiling.

resultsAmong 618 patients, a total of 214 cases (34.6%) achieved HBsAg clearance, namely 214 cases in group R and 404 cases in group NR. The R group was younger, had longer treatment, and had lower baseline HBsAg levels compared to the NR group. In 34 HBeAg-negative patients with chronic HBV infection, we studied the distribution of CD4 + and CD8 + T cells at different stages of differentiation. After 24 weeks of interferon therapy, responders exhibited increased CD4 + TCM and stable CD8 + TCM levels, along with decreased CD8 + TEMRA and Th2 cells. In contrast, non-responders showed reductions in TCM, elevated TEMRA, and Th2 cells. Responders exhibited a marked decline in PD-1 + CD8 + and CD160 + CD8 + T cells (at 0.97 and 0.95 times the baseline), whereas non-responders showed relative increases (at 1.74 and 1.55 times the baseline).

conclusionPeg-IFN-α may promote HBsAg clearance in selected HBeAg-negative patients with low antigen burden and partially reversible T-cell exhaustion.

Indexed as

Hepatitis B, ChronicHepatitis B virusInterferon-alphaT-Lymphocyte SubsetsAdultAntigens, CDAntiviral AgentsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesDNA, ViralFemaleFollow-Up StudiesHepatitis B e AntigensHepatitis B Surface AntigensHumansMaleAntigens, CDAntiviral AgentsDNA, ViralHepatitis B e AntigensHepatitis B Surface AntigensInterferon-alphaProgrammed Cell Death 1 ReceptorChronic HBV infectionHBsAg seroclearanceInhibitory receptorsT cell immunityT cell subsets

Identifiers

PMID41419829
PMCPMC12717683

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.